Kidswell Bio Corporation (TYO:4584)
141.00
-1.00 (-0.70%)
Nov 18, 2026, 10:14 AM JST
Kidswell Bio Revenue
Kidswell Bio had revenue of 1.21B JPY in the quarter ending September 30, 2026, a decrease of -22.46%. This brings the company's total for the last twelve months to 5.79B, down -12.42% year-over-year. In the fiscal year ending March 31, 2026, Kidswell Bio had annual revenue of 6.59B with 29.65% growth. That makes Kidswell Bio the 30,216th largest company in the world by revenue and 3,183rd in Japan.
Revenue (ttm)
5.79B
Revenue Growth
-12.42%
P/S Ratio
1.24
Revenue / Employee
180.88M
Employees
32
Market Cap
7.14B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.59B | 1.51B | 29.65% |
| Mar 31, 2025 | 5.08B | 3.51B | 223.90% |
| Mar 31, 2022 | 1.57B | 573.00M | 57.53% |
| Mar 31, 2021 | 996.00M | -81.00M | -7.52% |
| Mar 31, 2020 | 1.08B | 55.30M | 5.41% |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| StemCell Institute | 2.81B |
| Immuno-Biological Laboratories | 1.08B |
| Carna Biosciences | 756.57M |
| OncoTherapy Science | 712.00M |
| Nano Holdings | 210.00M |
| CellSeed | 161.00M |
| ADR Biomedical Holdings | 98.00M |
| Kubota Pharmaceutical Holdings | 12.77M |